1. STRATEGY PLANNING AT
KEMWELL INTERNATIONAL
PVT LTD
BY : LOHITH.D
MBA ILAM

2. CONTENTS
 COMPANY PROFILE
BRIEF HISTORY ABOUT THE COMPANY
COMPANY’S STRATEGIES, PARTNERSHIPS &
ACQUISITIONS.
FUTURE OBJECTIVES
REFERENCES.
VIDEO CLIPPLING OF THE COMPANY.

3. COMPANY PROFILE
• INDUSTRY TYPE
Global Contracting Manufacturing Organization for
Pharmaceuticals, Clinical & Biopharmaceutical
companies.
• CORPORATE HEADQUATERS
Bangalore, INDIA
• YEAR FOUNDED
1980

4. CONTINUED….
• KEMWELL FOUNDER
SUBHASH BAGARIA [CHAIRMAN & M.D]
• FACILITIES
INDIA – Analytical R&D, Formulation
Development, Clinical batch
production, Manufacturing on commercial
scale, Packaging and Global Distribution.
SWEDEN – Analytical & Mfg Services.
USA – Marketing & Sales.

5. • EMPLOYEES
1000+ worldwide
• COUNTRIES
Supply to over 80 countries worldwide.
• REGULATORY APPROVALS
USFDA, EMA & Japanese Regulatory.

6. HISTORY
 Kemwell , initially an API
manufacturing company
bought from an IISc scientist
with a turnover of Rs 20
lakh, and making losses of Rs
6 lakh annually.
It took some time, and a lot
of effort to bring the
company to the present
level, says Subhash
Bagaria, the founder and
chairman, Kemwell.

7. Bagaria says :
“ After taking over, Kemwell started doing its
own branded products, but were making more
losses. Later a close friend of his, in GSK advised
him to close it down since the competition was too
high, and we were very small. We closed it, we
thought of starting contract manufacturing.
Since that day, we are doing contract manufacturing
and nothing else. The moment we closed API
business and our own products, the company
stopped making losses” .

8. COMPANY’S
STRATEGIES, PARTNERSHIPS &
AQUISITIONS
1) Pure play strategy
a)The company’s strategy has been to
continuously grow itself in contract
manufacturing and nothing else.
b)Kemwell never looked at putting its own
brands again in the market and competing
with its customers. Bagaria believes, “It is best
to be a pure play player in contract
manufacturing. And that is the reason why we
are getting so many orders.”

9. c)Building long-term relationships for
commercial products is necessary for any large
CMO to sustain long-term growth.
d)Kemwell has long-standing relationships with
innovator companies such as
AstraZeneca, Bayer, GSK, J&J, Novartis and
Pfizer, for the Indian market. And to meet the
enlarged pipeline of projects, Kemwell has
expanded its manufacturing capacity in the
last few years.

10. The majority of dosage forms company offer’s
today, which marry European and Asian
strengths, are:
Solid dose tablets; uncoated, sugar-coated
and film-coated (solvent and aqueous) tablets;
suppositories; effervescent and bi-layer
tablets; hard gelatin capsules filled with
powder, granules, pellets or liquid-orals; semi-
solid creams, gels and ointments; and
controlled and psychotrophic drug substances.

12. 2) Upgrading of in-built FOX-PRO to SAP ERP in
2005
a) Modules like finance, material
management, production planning, quality
management, plant maintenance, sales &
distribution and asset management were
integrated on-line.
b) The major benefit being that as every
transaction could be displayed immediately
whenever any audit is done internally or by the
parent company, it was easier to churn out the

13. 3) Europe focus
With a long-term aim of establishing itself in
Europe, the company acquired Pfizer’s
manufacturing facility in Uppsala, Sweden in
2006.
The facility approved by US Food and Drug
Administration (FDA), the European Medicines
Agency (EMEA), and Japan’s regulatory
authority, supplies products to over 80
markets, including the US, Europe and Japan.

14. • The strategic acquisition resulted in significant
growth in Kemwell’s contract business, and
provided it the access to technology and
quality standards on a continuing basis.
• The addition of Pfizer’s manufacturing
capabilities to its operations have allowed
Kemwell to transfer some of the learning and
experience, from Europe to India, and has
enhanced in the expansion of its contract
manufacturing business.

15. • The acquisition also
provided Kemwell with
a global site to serve its
customer base, in
addition to its four sites
in Bangalore, thus
significantly reducing
customers’ sourcing
risks

16. 4) PARTNERSHIP WITH GLAXOSMITHKLINE(GSK)
Kemwell in partnership with GSK in NOV 2008
sets up a new R&D facility in Bangalore to
cater to GSK’s global oral healthcare
development projects.
Eg) SENSODYNE toothpaste

17. 5) Strategic alliance with Patheon - April 2009
Patheon a global service provider of drug
development and manufacturing services
based in Canada.

18. 6) Kemwell steps into Biological arena in 2009
Kemwell signed a technical alliance with
Boehringer Ingelheim , GERMANY to take its
first step into the biologics arena.

19. • The agreement with Boehringer Ingelheim is a
technical and marketing alliance.
• The overall purpose of the collaboration as
strategic partners is to offer customers at their
choice broader contract services and have a
shorter period of product development.
• A smooth technology transfer from the various
stages of clinical development and
manufacturing to the benefit of both
companies, the health market
and, ultimately, the patients..

20. • Boehringer Ingelheim is helping in
building Kemwell's new Greenfield
state-of-the-art facility which is
spread over 15,000 sq m and is
designed for process
development, fermentation, purifi
cation and formulation of
biologics for early-phase pre-
clinical and clinical studies
design, cell-line
development, process
development and transfers, and

21. KEMWELL’S REVENUE
• During the last fiscal, Kemwell revenues stood
at Rs 300 crore and it is now targeting Rs 350
crore from the current fiscal. The new facility
will add another Rs 250 crore, once it is fully
utilised.

22. FUTURE OBJECTIVES
• Over the next two-five years, Kemwell
Biopharma will expand its client roster to
service small biopharmaceutical companies in
developed countries like
USA, Europe, Australia etc. to help them
reduce their prohibitively high costs of R&D by
offering biologics contract manufacturing
facilities.

23. REFERENCES
1) www.kemwellbiopharma.com
2) Biospectrumindia.cio/.com>biobusiness
3) www.expresspharmaonline.com
4) www.kemwell.com

24. VIDEO CLIPPING